OncoGenex to Present at Credit Suisse Healthcare Investor Conference
BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 5, 2013 /CNW/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2013 at 8:30 a.m. MST at the Phoenician Hotel in Scottsdale, Arizona.
A live audio webcast can be accessed through the Investor Relations page of the OncoGenex website at www.oncogenex.com. The webcast replay will be archived for 60 days.
Highlights from the presentation can be followed on the new OncoGenex Investor Relations Twitter account at: http://twitter.com/@OncoGenex_IR.
ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.
SOURCE: OncoGenex Pharmaceuticals, Inc.
![](http://rt.newswire.ca/rt.gif?NewsItemId=C4162&Transmission_Id=201311050630CANADANWCANADAPR_C4162&DateId=20131105)
Media Contact: Jaime Welch, [email protected], 604-630-5403 or Investor Relations Contact: Susan Specht, [email protected], 425-686-1535
http://www.OncoGenex.com
Share this article